872
Views
0
CrossRef citations to date
0
Altmetric
Genetic Disease

Re: Response letter to Sanofi’s communication related to “the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States”

, , , , & ORCID Icon
Pages 581-583 | Received 28 Mar 2023, Accepted 29 Mar 2023, Published online: 17 Apr 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.